NDAORALTABLETPriority Review
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
6/8 — Strong
Priority Review
MAVYRET (glecaprevir and pibrentasvir) by AbbVie is p-glycoprotein inhibitors [moa]. First approved in 2017.
Drug data last refreshed 8h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAVYRET is an oral, fixed-dose combination of glecaprevir and pibrentasvir approved by the FDA in August 2017 for the treatment of chronic hepatitis C virus (HCV) infection. It works as an NS5A inhibitor and P-glycoprotein inhibitor, directly targeting viral replication machinery. MAVYRET represents a pan-genotypic, all-oral DAA regimen offering high cure rates across HCV genotypes 1-6.
$0.233BPart D
Peak10.3 years to LOEPeak-stage HCV franchise product with stable Part D spending; brand teams likely focused on market maintenance and patient access optimization rather than growth expansion.
Mechanism of Action
P-Glycoprotein Inhibitors
Pharmacologic Class:
Hepatitis C Virus NS5A Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Viekira Pak or Mavyret Treatment for Patient With Chronic Kidney Disease and Hepatitis C
Started Feb 2017
10 enrolled
Chronic Kidney DiseaseChronic Hepatitis C
Why This Matters for Your Career
Worked on MAVYRET at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.